Page 3 - Dr Reddy's

Analysts slash FY22 profit estimates; telecom, PSU banking firms suffer

An analysis done by Motilal Oswal Financial Services (MOFSL) shows, health care and technology are the only two sectors which have seen an upgrade in FY22 earnings

Healthy growth in India, US helps Dr Reddy's post strong Q2 performance

Wockhardt buy, Covid portfolio aid India business growth

Covid-19: Dr Reddy's engages Indian partners to develop Sputnik V

Sputnik V is also undergoing Phase 3 clinical trials in Russia and other parts of the globe on 40,000 volunteers

Dr Reddy's Laboratories shuts all units after cyber attack on servers

Security breach comes days after firm got approval to conduct trials for Covid-19 vaccine candidate Sputnik V

Dr Reddy's gets nod for 2/3 vaccine trial; Key updates about the virus

A PMO release said three vaccines are in advanced stages of development in India, out of which two are in Phase II and one is in Phase-III

India trials for Russia's Covid vaccine may start in few weeks: Dr Reddy's

The trials are part of a deal between the Russian Direct Investment Fund and Dr Reddy's.

Russian vaccine on its way to India, pact signed with Dr Reddy's for trials

Talks are also on with five major Indian manufacturers here to produce the vaccine for India and the world

Russia to supply 100 million doses of Sputnik V vaccine to Dr Reddy's

The Russian Direct Investment Fund said that the deliveries could potentially begin in late 2020 subject to completion of successful trials and registration of the vaccine in India

Dr Reddy's Laboratories launches drug to treat infections in US market

Ciprodexis used in adults and children 6 months of age or older to treat certain types of infections caused by certain germs called bacteria

Dr Reddy's: Strong Q1 show in spite of disruption lifts sentiment

Normalising US and India sales likely to drive earnings in FY21

Dr Reddy's Q1 PAT falls 13% to Rs 579 cr, revenue up by 15% to Rs 4,417 cr

Commenting on the results, co-chairman and MD, G V Prasad said "the current quarter's financial performance has been strong across all parameters

Aarti Drugs to Tata Comm: Earnings rise for 15 firms in Covid-19 economy

These companies reported an increase in revenue and/or profit before tax for the March quarter

Sun Pharma stock sheds 15% on price fixing concerns, slow portfolio ramp-up

The near-term worry for the company is the ongoing investigation by the US Department of Justice related to price fixing and cartelisation by generic companies

Dr Reddy's gets 1 observation from USFDA after inspecting Hyderabad plant

Earlier, the drug major had said that the US health regulator has issued a Form 483 with two observations after inspecting the facility but later it was issued revised Form 483 with one observation

Wockhardt sells part of branded biz to Dr Reddy's for Rs 1850 crore

Deal would help Wockhardt focus on international operations, novel pipeline R&D

Dr Reddy's to acquire part of Wockhardt's India business for Rs 1,850 crore

The agreement comprises a portfolio of 62 brands in multiple therapy areas such as respiratory, neurology, and dermatology.

Dr Reddy's reaping benefits of domestic market focus, outperforms peers

Firm has outperformed domestic pharma market in 7 of last 8 quarters

Dr Reddy's launches cancer treatment drug Bortezomib in the US market

Bortezomib is an active ingredient similar to that of the once blockbuster cancer treatment Velcade of Millennium Pharmaceuticals

Indian pharma cos with bigger US presence face more FDA scrutiny: Analysts

Big entities such as Aurobindo and Dr Reddy's have been currently filing for new product approvals from multiple sites

Develop entire value chain: Dr Reddy's MD tells pharma companies

US-China trade war is going to give us a window of opportunity to expand our industry, says G V Prasad